Lutetium-177 and Actinium-225 sit at two ends of the same story: an established beta emitter behind approved radioligand therapies like ¹⁷⁷Lu‑DOTATATE and ¹⁷⁷Lu‑PSMA‑617, and an emerging alpha emitter now advancing through early-phase trials on the same targeting vectors.

This Comecer scientific webinar brings the two together, from isotope production to clinical practice.

Mario Malinconico, Scientific Leader at Comecer, opens with the market landscape for radioligand and targeted alpha therapy and the production routes behind both isotopes, reactor-based for Lu-177, and the emerging generator, cyclotron-based routes and more for Ac-225, along with the Comecer technology that supports them.

Guest speaker Dr. Shuichi Shiratori (Chulalongkorn University, Bangkok, Thailand) then shares his lab's work and clinical experience with Lu-177 and Ac-225 radiopharmaceuticals, including a look inside his in human clinical trials.

Register now